Biotech News

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

Aprea Therapeutics (APRE)Aprea Therapeutics2026-06-25 13:46 ESTFinancing

Financing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Management and additional new and existing investors DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision

Open original release

Related news

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

View all latest news

Aprea Therapeutics

Aprea Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

APREAprea Therapeutics2026-06-26 09:24 EST

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

APREAprea Therapeutics2026-06-26 09:24 EST

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

APREAprea Therapeutics2026-06-26 09:24 EST

Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan

APREAprea Therapeutics2026-06-26 09:24 EST

Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

APREAprea Therapeutics2026-06-26 09:24 EST

Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States